Informed Consent Form Template for Research

CLINICAL RESEARCH PARTICIPANT INFORMED CONSENT AND AUTHORIZATION FORM

DOCUMENT CONTROL

• Effective Date: [Effective Date, e.g., October 24, 2023]
• Version: [Version Number, e.g., 2.4]
• Jurisdiction/Scope: [Governing State/Country, e.g., State of California, United States]
• Protocol ID / IRB Number: [Institutional Review Board Protocol Number]

---

1. LEGAL NOTICE & COMPLIANCE DISCLAIMER

This document contains legal terms and structural frameworks for clinical research compliance. It must be reviewed and approved by a qualified Institutional Review Board (IRB) and legal counsel specializing in human subjects research prior to deployment. Regulatory standards governed by the U.S. Department of Health and Human Services (45 CFR 46), the Food and Drug Administration (21 CFR 50 and 56), and applicable local privacy frameworks (such as HIPAA or GDPR) apply directly to the execution of this agreement. This template does not constitute formal legal advice.

---

2. PARTIES & DEFINITIONS

This Informed Consent Form ("Form") is entered into by and between:

• Principal Investigator (PI): [Principal Investigator Full Name, Title, and Affiliation]
• Research Institution / Sponsor: [Legal Entity Name of Institution or Corporate Sponsor]
• Participant ("You" / "Your"): [Participant Full Legal Name]

Definitions:

• "Study": The clinical research investigation titled [Full Official Study Title].
• "PHI": Protected Health Information collected, generated, or utilized during the course of the Study, subject to applicable privacy laws.
• "Data": All de-identified and identifiable metrics, biological samples, and digital recordings acquired pursuant to Study protocols.

---

3. OPERATIVE CLAUSES & TERMS

1. Purpose of the Research Study

You are being asked to participate in a research study conducted by [Principal Investigator Name] at [Institution/Facility Name]. The purpose of this Study is to [Provide a clear, concise plain-language description of the research objectives and hypotheses]. Approximately [Total Number] participants will take part in this Study globally.

2. Voluntary Participation

Your participation in this Study is entirely voluntary. You may refuse to participate, or you may withdraw your consent and discontinue participation at any time without penalty, loss of benefits, or compromise to your standard medical care.

3. Study Procedures and Duration

If you agree to participate, you will be asked to complete the following procedures:

1. [Detailed Procedure 1, e.g., Attend X in-person clinic visits over Y months]
2. [Detailed Procedure 2, e.g., Undergo diagnostic imaging / blood draws]
3. [Detailed Procedure 3, e.g., Complete daily digital surveys via secure application]

The total duration of your participation will be approximately [Number of Weeks/Months/Years], which includes [Number] follow-up touchpoints.

4. Risks, Discomforts, and Inconveniences

Participation in this Study may involve foreseeable risks, including but not limited to:

• Physical Risks: [e.g., Mild bruising, infection at needle insertion sites, temporary fatigue]
• Psychological/Social Risks: [e.g., Emotional distress during sensitive questionnaires, potential loss of confidentiality]
• Inconveniences: Time commitment, fasting requirements, and travel obligations.

The researchers will employ all standard safety protocols to minimize these risks. Additional unforeseen risks may arise.

5. Potential Benefits

• Direct Benefits: You may or may not receive direct medical benefit from participating in this Study. Potential benefits include [e.g., Access to novel diagnostic assessments, close clinical monitoring].
• Indirect Benefits: Data gathered from this Study may contribute to generalized scientific knowledge and improve future care protocols for [Target Condition].

6. Confidentiality and Data Protection (HIPAA Authorization)

Your identity and Study Data will be kept confidential to the extent permitted by law. By signing this Form, you authorize the Principal Investigator, the Research Sponsor, regulatory authorities (e.g., FDA, OHRP), and the Institutional Review Board ([IRB Name]) to access, inspect, and copy your medical records and Study Data.

• Data De-identification: Data stripped of direct identifiers may be used for future research or published in scientific journals without your additional consent.
• Certificate of Confidentiality: This research is protected by a Certificate of Confidentiality issued by [Agency Name], preventing researchers from being forced to disclose identifiable information in legal proceedings.

7. Compensation and Costs

• Compensation: You will receive [Financial Amount or "No financial compensation"] for your time, travel, and completion of Study milestones, disbursed via [Disbursement Method]. Prorated compensation will be provided if you withdraw early.
• Costs: You, your health insurance, or the Research Sponsor will be responsible for costs associated with standard medical care. You will not incur direct financial costs for investigational procedures unique to this Study.

8. Injury Resulting from Participation

If you suffer physical injury as a direct result of participating in this Study, immediate medical treatment will be available at [Name of Facility/Hospital]. Financial compensation for lost wages, specialized care, or long-term disability depends on the policies of the Sponsor, [Sponsor Name]. This document does not waive any legal rights you may have to seek compensation through standard legal channels.

9. Right to Withdraw or Be Withdrawn

You retain the absolute right to withdraw from the Study at any time. Furthermore, the Principal Investigator or Sponsor may terminate your participation without your consent if:

• You fail to follow critical Study instructions or protocols.
• Continuing the Study would endanger your health or safety.
• The entire research protocol is terminated by the IRB or regulatory authorities.

10. Contact Information

For questions regarding the Study, research-related injuries, or to report adverse events, contact:

• Primary Contact: [Name / Title]
• Telephone Number: [Phone Number]
• Email Address: [Email Address]
• 24/7 Emergency Line: [Emergency Phone Number]

For questions regarding your rights as a research participant, or to lodge complaints, contact:

• Institutional Review Board (IRB) Office: [IRB Entity Name]
• IRB Telephone Number: [IRB Phone Number]

---

4. SIGNATURES & ACKNOWLEDGMENT BLOCK

By signing below, you acknowledge that:

1. You have read and fully understand this Informed Consent and Authorization Form.
2. All of your questions regarding the Study, its risks, and its benefits have been answered to your satisfaction.
3. You freely and voluntarily choose to participate in the research described herein.
4. You have received a signed and dated copy of this document for your personal records.

PARTICIPANT / LEGAL REPRESENTATIVE

• Full Legal Name (Printed): ________________________________________________
• Signature: ________________________________________
• Date: ____ / ____ / 20___
• Capacity (if signing for participant): [ ] Self [ ] Parent [ ] Legal Guardian [ ] Power of Attorney

---

PERSON OBTAINING CONSENT

I certify that I have accurately explained the nature, purpose, potential risks, and benefits of this Study to the participant, and that they have freely given informed consent.

• Investigator / Designee Name (Printed): _____________________________________
• Signature: ________________________________________
• Date: ____ / ____ / 20___

---

5. STEP-BY-STEP EXECUTION GUIDE

1. IRB Review & Approval: Submit this template, along with the full protocol and recruitment materials, to the governing Institutional Review Board (IRB) or Ethics Committee. Do not alter core compliance clauses without prior IRB authorization.
2. Pre-Consent Discussion: Conduct a thorough, private consultation with the prospective participant. Ensure adequate time is provided for the individual to review terms, ask questions, and consult family members or independent advisors.
3. Execution & Duplicate Issuance: Ensure all fillable brackets are completed accurately. Both the participant (or their legally authorized representative) and the authorized study designee must sign and date the document prior to the initiation of any research-related procedures. Provide a fully executed copy to the participant immediately.
4. Archival & Compliance Tracking: File the original signed document in the secure Investigator Site File (ISF) or regulatory binder, maintaining strict audit trails in compliance with GCP (Good Clinical Practice) standards and applicable data privacy regulations.